Stereotactic ablative body radiotherapy (SABR) for locally advanced exocrine pancreatic cancer

Topic Status Complete

Stereotactic ablative body radiotherapy (SABR) for locally advanced exocrine pancreatic cancer.

Summary

 

Health Technology Wales researchers searched for evidence on stereotactic ablative body radiotherapy (SABR) for locally advanced exocrine pancreatic cancer. HTW’s Assessment Group decided not to progress this topic further due to the development of commissioning arrangements by Welsh Health Specialised Services Committee.

Topic Exploration Report

TER426 11.2022

Access our guidance

Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it.

  • We may like to contact you by email to find out more about how you used the documents.

  • This field is for validation purposes and should be left unchanged.